Skip to main content
. Author manuscript; available in PMC: 2019 Apr 1.
Published in final edited form as: Cell Signal. 2018 Jan 10;44:92–102. doi: 10.1016/j.cellsig.2018.01.009

Table 1.

Clinical Trials of MLN4924

Clinicaltrial. gov identifier Phase Tumor type Time initiated With conbination Antitumor activity Ref
NCT00677170 I Solid tumor May 2008 Alone 9 SDs [61]
NCT00722488 I HL, HM, MM, lymphoma July 2008 Alone 1 PR [62]
NCT00911066 I AML, ALL, MS May 2009 Alone
With azacitidine		 4 CRs [63]
NCT01011530 I Metastatic melanoma November 2009 Alone 9 SDs
1 PR		 [64]
NCT01862328 Ib Solid tumor May 2013 With docetaxel
With gemcitabine
With carboplatin
+paclitaxel		 NR
NCT01814826 Ib AML March 2013 With azacitidine 6 CRs
4 PRs		 [65]
NCT02610777 II AML November 2015 with azacitidine versus single-agent azacitidine NR

AML: Acute myeloid leukemia; ALL: acute lymphoblastic leukemia; CR: Complete response; HL: Hodgkin lymphoma; HM: hematologic malignancies; MM: multiple myeloma; MS: myelodysplastic syndrome; NR: not reported; PR: partial response; SD: stable disease.